Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report

BACKGROUND: Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches. CASE PRESENTATION: We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer zu Schwabedissen, Henriette E, Siegmund, Werner, Kroemer, Heyo K, Rollnik, Jens D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192324/
https://www.ncbi.nlm.nih.gov/pubmed/25280537
http://dx.doi.org/10.1186/1756-0500-7-688
_version_ 1782338759185924096
author Meyer zu Schwabedissen, Henriette E
Siegmund, Werner
Kroemer, Heyo K
Rollnik, Jens D
author_facet Meyer zu Schwabedissen, Henriette E
Siegmund, Werner
Kroemer, Heyo K
Rollnik, Jens D
author_sort Meyer zu Schwabedissen, Henriette E
collection PubMed
description BACKGROUND: Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches. CASE PRESENTATION: We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxicity (myalgia and moderate creatine kinase elevation). CONCLUSIONS: The obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9*3 variant in combination with multidrug resistance-associated protein MRP2 -24C > T functions as risk factor predisposing to experience drug-drug interaction combing those drugs.
format Online
Article
Text
id pubmed-4192324
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41923242014-10-11 Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report Meyer zu Schwabedissen, Henriette E Siegmund, Werner Kroemer, Heyo K Rollnik, Jens D BMC Res Notes Case Report BACKGROUND: Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches. CASE PRESENTATION: We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxicity (myalgia and moderate creatine kinase elevation). CONCLUSIONS: The obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9*3 variant in combination with multidrug resistance-associated protein MRP2 -24C > T functions as risk factor predisposing to experience drug-drug interaction combing those drugs. BioMed Central 2014-10-03 /pmc/articles/PMC4192324/ /pubmed/25280537 http://dx.doi.org/10.1186/1756-0500-7-688 Text en © Meyer zu Schwabedissen et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Meyer zu Schwabedissen, Henriette E
Siegmund, Werner
Kroemer, Heyo K
Rollnik, Jens D
Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report
title Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report
title_full Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report
title_fullStr Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report
title_full_unstemmed Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report
title_short Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report
title_sort creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the cyp2c9*3 and abcc2 -24c > t variants: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192324/
https://www.ncbi.nlm.nih.gov/pubmed/25280537
http://dx.doi.org/10.1186/1756-0500-7-688
work_keys_str_mv AT meyerzuschwabedissenhenriettee creatinekinaseelevationcausedbyacombinationoffluvastatinandtelmisartaninapatientheterozygousforthecyp2c93andabcc224ctvariantsacasereport
AT siegmundwerner creatinekinaseelevationcausedbyacombinationoffluvastatinandtelmisartaninapatientheterozygousforthecyp2c93andabcc224ctvariantsacasereport
AT kroemerheyok creatinekinaseelevationcausedbyacombinationoffluvastatinandtelmisartaninapatientheterozygousforthecyp2c93andabcc224ctvariantsacasereport
AT rollnikjensd creatinekinaseelevationcausedbyacombinationoffluvastatinandtelmisartaninapatientheterozygousforthecyp2c93andabcc224ctvariantsacasereport

Ejemplares similares